4,449 results match your criteria Haemophilia[Journal]


Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.

Haemophilia 2018 Dec 6. Epub 2018 Dec 6.

Research Department of Haematology, University of London Cancer Institute, London, UK.

Introduction: The variety of treatment for haemophilia B (HB) has recently improved with the emergence of both AAV-based gene therapy and bioengineered human factor IX (hFIX) molecules with prolonged half-life due to fusion to either albumin (Alb) or immunoglobulin Fc fragment (Fc).

Aim: Adeno-associated viral vectors (AAV) mediating expression of hFIX-Alb and hFIX-Fc fusion proteins was investigated for gene therapy of HB to explore if their extended half-life translates to higher plasma levels of FIX.

Methods: Single-stranded cross-packaged AAV2/8 vectors expressing hFIX-Alb, hFIX-Fc and hFIX were evaluated in vitro, and in mice. Read More

View Article
December 2018

Posturographic and ankle muscle activation characteristics in patients with haemophilia.

Haemophilia 2018 Dec 6. Epub 2018 Dec 6.

Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany.

Introduction: The objective of this work was to examine the interrelations of posturographic and surface EMG (SEMG) characteristics of ankle muscles in patients with haemophilia while standing naturally.

Methods: Surface EMG of five bilaterally recorded ankle muscles was conducted in 24 patients with haemophilia (PwH, age: 42 [11] years, mean [SD], 22 A, 2 B, 21 severe, 3 moderate) with median (quartiles) WFH orthopaedic joint score of 30 (20/39) points and 24 non-haemophilic controls (Con, age: 42 [12]). Force plate (IBS) signals were captured simultaneously during bipedal stance with eyes open. Read More

View Article
December 2018
2 Reads

Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains.

Haemophilia 2018 Dec 6. Epub 2018 Dec 6.

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Background: The Patient Reported Outcomes, Burdens and Experiences (PROBE) study aims to develop and validate questionnaire for assessing health status in patients with haemophilia and participants without bleeding disorders.

Objective: To investigate the test-retest properties of the PROBE questionnaire.

Methods: The PROBE questionnaire covers four domains and is comprised of 29 questions. Read More

View Article
December 2018
1 Read

Over two decades of orthopaedic surgery in patients with inhibitors-Quantifying the complication of bleeding.

Haemophilia 2018 Dec 3. Epub 2018 Dec 3.

Department of Trauma & Orthopaedics, Royal Free Hospital, London, UK.

Patients with haemophilia who have developed inhibitors against factor VIII (FVIII) or factor IX present a significant concern to those surgeons who operate on them. The evidence base for bypassing agents such as recombinant factor VIIa and activated prothrombin complex concentrate has amassed over several decades. The literature is open to positive interpretation on the successful use of these agents in the treatment of inhibitor-positive patients. Read More

View Article
December 2018

Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.

Haemophilia 2018 Nov 29. Epub 2018 Nov 29.

Department of Haematology, Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Background: Both one-stage (OSA) and chromogenic substrate assays (CSA) are used to measure factor VIII (FVIII) activity. Factors explaining analytical variation in FVIII activity levels are still to be completely elucidated.

Aim: The aim of this study was to investigate and quantify the analytical variation in OSA and CSA. Read More

View Article
November 2018
1 Read

Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: A qualitative review.

Haemophilia 2018 Nov;24(6):862-872

Pfizer, Ballerup, Denmark.

Recombinant prophylactic treatment (PTX) has greatly improved morbidity, mortality and health-related quality of life (HRQoL) in patients with severe haemophilia. Yet, treatment adherence appears suboptimal in adolescents and young adults with haemophilia (YWH). Young patients experience major biopsychosocial changes challenging their adherence through the transition from parental to self-care, from paediatric to adult care. Read More

View Article
November 2018
3 Reads

Thromboelastometry profiles after "in vitro" addition of a new plasma-derived factor V concentrate to whole blood from parahaemophilia patients.

Haemophilia 2018 Nov 23. Epub 2018 Nov 23.

Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine-DIMED, Regional Centre for Haemophilia and Thrombophilia Centre, Padua University Hospital, Padua, Italy.

View Article
November 2018
1 Read

A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor.

Haemophilia 2018 Nov 23. Epub 2018 Nov 23.

UC Davis, Sacramento, California.

View Article
November 2018
3 Reads

Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease: A nationwide register study in Sweden.

Haemophilia 2018 Nov 23. Epub 2018 Nov 23.

Department of Translational Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.

Introduction: It has been hypothesized that persons with von Willebrand disease (VWD) may be protected against arterial thrombosis despite having atherosclerosis.

Aim: To calculate a nationwide estimate of the absolute and comparative burden of cardiovascular disease (CVD) hospitalization and mortality among persons with VWD using birthdate and sex-matched comparisons from the general population in Sweden.

Methods: Persons with VWD regardless of the type and severity, diagnosed by a medical doctor, who lived in Sweden for some time during the observation period 1987 through 2008 were included. Read More

View Article
November 2018
1 Read
2.600 Impact Factor

Samuel Armstrong Lane's first successful treatment of haemophilia with blood transfusion in 1840: Could this also be the first successful bypassing therapy?

Haemophilia 2018 Nov 21. Epub 2018 Nov 21.

Department of Medicine, University of Saskatchewan College of Medicine, Saskatoon, Saskatchewan, Canada.

View Article
November 2018
1 Read

Utility valuation of health states for haemophilia and related complications in Europe and in the United States.

Haemophilia 2018 Nov 21. Epub 2018 Nov 21.

Patient-Centered Outcomes, Mapi, an ICON plc Company, Lyon, France.

Introduction: There is currently a paucity of health utility data describing the consequences of haemophilia and related complications.

Aim: To quantify the impact of distinct stages of severity of haemophilia and disease-related complications on health-related quality of life, expressed as health utilities in Europe and the United States.

Methods: Nine health state descriptions were developed based on literature review and interviews with haematologists and haemophilia patients. Read More

View Article
November 2018
2 Reads

Ranges and drivers of risk associated with sports and recreational activities in people with haemophilia: results of the Activity-Intensity-Risk Consensus Survey of US physical therapists.

Haemophilia 2018 Nov;24 Suppl 7:5-26

Novo Nordisk Inc., Plainsboro, New Jersey.

Introduction: Limited evidence describes physical activity-associated bleeding risks for people with haemophilia, and risks are usually described only generically.

Aim: To assess activity-specific ranges of risk for joint, soft tissue and head bleeds by identifying inherent and modifiable risk factors associated with each activity, based on opinions of expert physical therapists (PTs).

Methods: Physical therapists from US haemophilia treatment centres (HTCs) participated in a survey of 101 physical activities. Read More

View Article
November 2018
2 Reads

Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score.

Haemophilia 2018 Nov 16. Epub 2018 Nov 16.

Pfizer SLU, Madrid, Spain.

Aim: The use of musculoskeletal ultrasound (MSK-US) following protocols for haemophilic arthropathy and the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score can help standardize monitoring in haemophilia. This study evaluated the joint status (elbows, knees and ankles) of patients with haemophilia B (HB) in Spain using MSK-US and the HEAD-US score.

Methods: Haemophilia B patients ≥14 years old were included in this observational, multicentre, cross-sectional study, regardless of their clinical condition, HB severity and treatment received. Read More

View Article
November 2018
12 Reads
2.600 Impact Factor

Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis.

Haemophilia 2018 Nov 15. Epub 2018 Nov 15.

Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Introduction: Bleeding assessment tools and laboratory phenotyping often remain inconclusive in patients with a haemorrhagic diathesis.

Aim: To describe the phenotype and genetic profile of patients with a bleeding tendency.

Methods: Whole exome sequencing (WES) was incorporated in the routine diagnostic pathway of patients with thrombocytopenia (n = 17), platelet function disorders (n = 19) and an unexplained bleeding tendency (n = 51). Read More

View Article
November 2018
2 Reads

Emicizumab: Review of the literature and critical appraisal.

Haemophilia 2018 Nov 15. Epub 2018 Nov 15.

Rush University, Chicago, Illinois.

Introduction: Emicizumab-kywh (ACE910) is a recombinant, humanized, asymmetric bispecific antibody that functions to bring activated FIX (FIXa) and zymogen FX into an appropriate steric conformation to medicate the activation of FX to FXa thereby mimicking the cofactor function of FVIIIa.

Aim: The objective of this manuscript was to review the development and potential role for emicizumab in the treatment of patients with haemophilia A with and without inhibitors.

Methods: A Cochrane Library and PubMed (MEDLINE) search focusing on emicizumab in haemophilia was conducted. Read More

View Article
November 2018
7 Reads

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Haemophilia 2018 Nov 14. Epub 2018 Nov 14.

University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Introduction: Persons with haemophilia A (PwHA) with inhibitors to factor VIII often experience decreased health-related outcomes. In HAVEN 1 (NCT02622321), there was a statistically significant reduction in bleeding with emicizumab prophylaxis versus no prophylaxis.

Aim: Describe health-related outcomes in PwHA with inhibitors in HAVEN 1. Read More

View Article
November 2018
1 Read

Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population.

Haemophilia 2018 Nov 14. Epub 2018 Nov 14.

Department of Haematology, Christian Medical College, Vellore, India.

Introduction: Factor replacement therapy in treatment of haemophilia A is complicated by the production of neutralising antibodies known as inhibitors. The formation of inhibitors is multifactorial being associated with both genetic and environmental factors.

Aim: To document the prevalence of inhibitors in severe haemophilia in the community where most patients receive only infrequent episodic replacement therapy and evaluate the factors which could be contributing to it. Read More

View Article
November 2018
5 Reads

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia-specific instruments.

Haemophilia 2018 Nov 14. Epub 2018 Nov 14.

Van Creveldkliniek, Department of Hematology, University Medical Center, Utrecht, The Netherlands.

Introduction: Accurate assessment of joint health in persons with haemophilia is crucial. Several haemophilia-specific measurement tools are available, but an overview of the measurement properties is lacking.

Aim: To provide an overview of the measurement properties of haemophilia-specific measurement tools to assess clinical joint health. Read More

View Article
November 2018
1 Read

Sports participation and physical activity in patients with von Willebrand disease.

Haemophilia 2018 Nov 14. Epub 2018 Nov 14.

Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Introduction: Patients with bleeding disorders may experience limitations in sports participation and physical activity. Several studies on sports participation have been performed in haemophilia patients, but studies in patients with von Willebrand disease (VWD) are lacking.

Aim: We assessed the sports participation and physical activity of a large cohort of VWD patients. Read More

View Article
November 2018
5 Reads

Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP.

Haemophilia 2018 Nov 14. Epub 2018 Nov 14.

National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel.

Introduction: Frequent infusions and bleeds can impact on the health-related quality of life (HRQoL) of paediatric haemophilia B patients. rIX-FP (IDELVION ) is a fusion protein linking recombinant factor IX with recombinant albumin, and is associated with low bleeding rates with a weekly regimen, which could improve HRQoL.

Aims: To measure the effect of rIX-FP prophylaxis on the HRQoL of paediatric patients and treatment satisfaction in their caregivers using the Haemo-QoL and Hemo-SAT questionnaires, respectively. Read More

View Article
November 2018
6 Reads

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.

Haemophilia 2018 Nov 8. Epub 2018 Nov 8.

Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK.

Introduction: Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor (TFPI). In EXPLORER3 (phase 1b), a dose-dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship was confirmed between concizumab dose, free TFPI and TG potential.

Aim: Determine the association between concizumab exposure, PD markers (free TFPI; peak TG) and bleeding episodes to establish the minimum concizumab concentration for achieving sufficient efficacy. Read More

View Article
November 2018
5 Reads

Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus.

Haemophilia 2018 Nov 8. Epub 2018 Nov 8.

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

View Article
November 2018
6 Reads

Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study.

Haemophilia 2018 Nov 8. Epub 2018 Nov 8.

UK National Haemophilia Database, Manchester, UK.

Introduction: The THUNDER study provides an analysis of treatment patterns and outcomes in UK patients with severe or moderate haemophilia A (SHA/MHA) in 2015.

Methods: Patients with SHA or MHA registered with the UK National Haemophilia Database (NHD) were segregated by severity, inhibitor status and age. Haemophilia joint health score (HJHS) was derived from NHD records and treatment regimen and annualized bleed/joint-bleed rate (ABR/AJBR) from Haemtrack (HT) in HT-compliant patients. Read More

View Article
November 2018
4 Reads

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Haemophilia 2018 Nov 6;24(6):e391-e394. Epub 2018 Nov 6.

Hannover Medical School, Hannover, Germany.

Introduction: Turoctocog alfa is a recombinant factor VIII (FVIII) molecule, approved for treatment and prophylaxis of bleeding in patients with haemophilia A. In the guardian 1 (adolescents/adults) and guardian 3 (children) phase 3 trials, turoctocog alfa demonstrated a favourable efficacy and safety profile. Guardian 1 or 3 completers could enrol in the guardian 2 extension. Read More

View Article
November 2018
4 Reads

Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries.

Haemophilia 2018 Nov 5. Epub 2018 Nov 5.

Department of Haematology, Oslo University Hospital, Oslo, Norway.

Introduction: There are two major principles for coagulation factor replacement in the clinical management of surgical procedures in patients with haemophilia, repetitive bolus injections every 6-12 hours or administration of coagulation factor concentrates by continuous infusion.

Aim: The aim was to investigate the efficacy of simoctocog alfa (human-cl rhFVIII) delivered by continuous infusion for bleeding prophylaxis during surgery in patients with haemophilia A.

Methods: We investigated the use of continuous infusion with simoctocog alfa in haemophilia A patients undergoing major surgical procedures at Oslo University Hospital from September 2015 to March 2018. Read More

View Article
November 2018
4 Reads

Assessment of tensile mechanical properties of the Achilles tendon in adult patients with haemophilic arthropathy. Reproducibility study.

Haemophilia 2018 Oct 30. Epub 2018 Oct 30.

Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.

View Article
October 2018
3 Reads

Thromboelastography and thrombin generation assay in inherited afibrinogenemia.

Haemophilia 2018 Nov 21;24(6):e410-e416. Epub 2018 Oct 21.

Children's Hospital Los Angeles, Los Angeles, California.

Fibrinogen is a glycoprotein with a crucial role in blood coagulation. Upon enzymatic cleavage by thrombin, fibrinogen is converted from its soluble form to insoluble fibrin which is key structural protein of a clot. It also participates in platelet aggregation by binding to GPIIb/IIIa. Read More

View Article
November 2018

Improving access to haemophilia therapies-Beyond humanitarian aid.

Haemophilia 2018 Nov 12;24(6):e430-e432. Epub 2018 Oct 12.

Almar Therapeutics Pty Ltd, Melbourne, Victoria, Australia.

View Article
November 2018
3 Reads
2.600 Impact Factor

Investigating the relationship between the HJHS and HAL in routine clinical practice: A retrospective review.

Haemophilia 2018 Nov 8;24(6):988-994. Epub 2018 Oct 8.

Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.

Introduction: Comprehensive musculoskeletal assessment for monitoring joint health in haemophilia includes both physical assessment with Haemophilia Joint Health Score (HJHS) and assessment of self-reported function by Haemophilia Activities List (HAL).

Methods: Correlation between physical assessment and joint function was undertaken between HJHS and HAL in patients with SHA and SHB who had both assessments at the same visit over a one-year period.

Results: Data from 120 patients (96-SHA/24 = SHB) with a median age 33 years (range 19-73) were included. Read More

View Article
November 2018
1 Read

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Haemophilia 2018 Nov 8;24(6):921-929. Epub 2018 Oct 8.

Washington Center for Bleeding Disorders at Bloodworks Northwest, Seattle, Washington.

Introduction: Prospectively collected, real-world data on bleeds, haemophilic treatment and safety outcomes in persons with haemophilia A (PwHA) with factor VIII (FVIII) inhibitors are limited. A prospective, global, multi-centre, non-interventional study (NIS; NCT02476942) collected detailed real-world data in PwHA treated per local routine clinical practice.

Aim: To characterize bleeding rates, haemophilic treatment practices, prophylaxis adherence and adverse events (AEs) in adult/adolescent PwHA with inhibitors in the NIS. Read More

View Article
November 2018
2 Reads

Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients.

Haemophilia 2018 Nov 1;24(6):980-987. Epub 2018 Oct 1.

Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Introduction: Haemophilia is a recessive X-linked inherited bleeding disorder, whose typical symptom is spontaneous intra-articular haemorrhage leading to joint damage, which can be quantified by the Haemophilia Joint Health Score (HJHS). Arthropathy and other characteristics of haemophilic patients may reduce bone mineral density (BMD), increasing the risk for fragility fractures, which also may occur due to bone quality impairment.

Aim: To evaluate bone quantity by BMD and bone quality by Trabecular Bone Score (TBS), bone strain (BS) and hip structural analysis (HSA) in a haemophilic population, and to relate these parameters to general and specific risk factors for osteoporosis and to HJHS. Read More

View Article
November 2018
2 Reads

Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders.

Haemophilia 2018 Nov 27;24(6):e428-e430. Epub 2018 Sep 27.

Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, Padua, Italy.

View Article
November 2018

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Haemophilia 2018 Nov 24;24(6):911-920. Epub 2018 Sep 24.

Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.

Introduction: Prophylaxis with replacement factor IX (FIX) reduces bleeding frequency and improves quality of life in haemophilia B patients. With prophylaxis, the likelihood of bleeding is lowered with increasing trough levels. New products with extended half-life (EHL) can maintain high factor activity levels over prolonged periods, compared with standard FIX products. Read More

View Article
November 2018
1 Read

Impact of intermediate-dose prophylaxis on progression of haemarthropathy in patients with severe haemophilia A: A 10-year, single-centre experience in Korea.

Haemophilia 2018 Nov 24;24(6):e402-e409. Epub 2018 Sep 24.

Department of Pediatrics, Eulji University School of Medicine, Daejeon, Korea.

Aim: To determine the impact of 10-year intermediate-dose prophylaxis on haemarthropathy progression in patients with severe haemophilia A (SHA).

Methods: Prophylactic treatment with intermediate dose was given maximally for 10 years to 42 patients with SHA in a haemophilia treatment centre in Korea. Patients were divided into three groups based on prophylactic treatment started age: 1-10 (group A'), 11-20 (group B'), and ≥21 (group C'). Read More

View Article
November 2018
1 Read

Utility of a screening tool for haemostatic defects in a multicentre cohort of adolescents with heavy menstrual bleeding.

Haemophilia 2018 Nov 12;24(6):957-963. Epub 2018 Sep 12.

Division of Pediatric Hematology/Oncology, Dallas, Texas.

Introduction: Heavy menstrual bleeding (HMB) may be expected for many adolescents after menarche. Accurate assessment of HMB, a key component in the diagnosis of a haemostatic defect (HD), is a well-recognized challenge.

Aim: Our objective was to determine the diagnostic accuracy of an HMB-specific screening tool for HDs in adolescents with HMB, presenting to a secondary care setting. Read More

View Article
November 2018
1 Read

Orthotopic liver transplantation for haemophilia A may not always lead to a phenotypic cure of haemophilia A: A case report.

Haemophilia 2018 Nov 3;24(6):e420-e422. Epub 2018 Sep 3.

Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.

View Article
November 2018

Congenital coagulation factor X deficiency: Genetic analysis of five patients and functional characterization of mutant factor X proteins.

Haemophilia 2018 Sep 28;24(5):774-785. Epub 2018 Aug 28.

Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.

Congenital factor X (FX) deficiency is a rare bleeding disorder that is inherited as an autosomal recessive trait. In this study, a genetic analysis of the FX gene was performed in five families with this disorder. Four heterozygous mutations [p. Read More

View Article
September 2018
1 Read

Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors.

Haemophilia 2018 Nov 24;24(6):e417-e420. Epub 2018 Aug 24.

Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

View Article
November 2018
8 Reads

Positioning extended half-life concentrates for future use: a practical proposal.

Haemophilia 2018 Sep 24;24(5):e369-e372. Epub 2018 Aug 24.

Department of Paediatric Haematology, Erasmus University Medical Centre - Sophia Children's Hospital, Rotterdam, The Netherlands.

View Article
September 2018

Haemophilia care in Latin America: Assessment and perspectives.

Haemophilia 2018 Nov 24;24(6):e395-e401. Epub 2018 Aug 24.

Children´s National Hospital, Caja Costarricense de Seguro Social, San Jose, Costa Rica.

Introduction: The study is the first application of the Principles of Haemophilia Care for Europe (PHCE) in other regions of the world, specifically in Latin America.

Objective: To identify strengths in the care of haemophilia, and the aspects that should be improved.

Methods: The information was obtained through a questionnaire designed according to the PHCE and answered by specialists in mid-2016. Read More

View Article
November 2018
3 Reads

Defining patient value in haemophilia care.

Haemophilia 2018 Jul;24(4):516-518

Department of Paediatric Haematology, Erasmus Medical Center - Sophia Children's hospital, Rotterdam, the Netherlands.

View Article
July 2018
9 Reads

A changing haemophilia world: Opportunities and challenges for the Haemophilia journal.

Authors:
Cedric Hermans

Haemophilia 2018 Jul;24(4):514-515

Haemostasis and Thrombosis Unit, Haemophilia Clinic, Division of Haematology, St-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium.

View Article
July 2018
1 Read